...
首页> 外文期刊>International journal of antimicrobial agents >Potential role of the cardiovascular non-antibiotic (helper compound) amlodipine in the treatment of microbial infections: Scope and hope for the future
【24h】

Potential role of the cardiovascular non-antibiotic (helper compound) amlodipine in the treatment of microbial infections: Scope and hope for the future

机译:心血管非抗生素(辅助化合物)氨氯地平在微生物感染治疗中的潜在作用:范围和对未来的希望

获取原文
获取原文并翻译 | 示例
           

摘要

The appearance of multiresistant bacterial strains coupled with the globally ongoing problem of infectious diseases point to the imperative need for novel and affordable antimicrobial drugs. The antibacterial potential of cardiovascular non-antibiotics such as amlodipine (AML), dobutamine, lacidipine, nifedipine and oxyfedrine has been reported previously. Of these drugs, AML proved to have the most significant antibacterial activity against Gram-positive and Gram-negative bacteria. Time-kill curve studies indicate that this Ca~(2+) channel blocker exhibits bactericidal activity against Listeria monocytogenes and Staphylococcus aureus. AML could protect against murine listeriosis and salmonellosis at doses ranging within its maximum recommended human or non-toxic ex vivo dose. AML acts as a 'helper compound' in synergistic combination with streptomycin against several Gram-positive and Gram-negative bacterial strains in vitro as well as in the murine salmonellosis model in vivo. The present review focuses on the possible use of cardiovascular non-antibiotics such as AML as auxiliary compound targets for synergistic combinations in infections and hypertension conditions, rationalised on the basis of the activities of the compounds.
机译:多抗性细菌菌株的出现,加上全球范围内持续存在的传染病问题,表明迫切需要新型和负担得起的抗菌药物。先前已报道了心血管非抗生素(如氨氯地平(AML),多巴酚丁胺,拉西地平,硝苯地平和奥昔芬碱)的抗菌潜力。在这些药物中,AML被证明对革兰氏阳性和革兰氏阴性细菌具有最显着的抗菌活性。时间杀伤曲线研究表明,该Ca〜(2+)通道阻滞剂对单核细胞增生李斯特菌和金黄色葡萄球菌具有杀菌活性。 AML可在其建议的最大人类或无毒离体剂量范围内,预防鼠李斯特菌病和沙门氏菌病。在体外以及在体内鼠沙门氏菌病模型中,AML都可与链霉素协同结合以对抗多种革兰氏阳性和革兰氏阴性细菌菌株,起到“辅助化合物”的作用。本综述着重介绍了可能将心血管非抗生素(例如AML)用作在感染和高血压情况下协同联合治疗的辅助化合物靶标,并根据这些化合物的活性进行了合理化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号